Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A comprehensive survey of coronaviral main protease active site diversity in 3D: Identifying and analyzing drug discovery targets in search of broad specificity inhibitors for the next coronavirus pandemic.
Lubin JH, Martinusen SG, Zardecki C, Olivas C, Bacorn M, Balogun M, Slaton EW, Wu AW, Sakeer S, Hudson BP, Denard CA, Burley SK, Khare SD. Lubin JH, et al. Among authors: khare sd. bioRxiv [Preprint]. 2023 Jan 31:2023.01.30.526101. doi: 10.1101/2023.01.30.526101. bioRxiv. 2023. PMID: 36778399 Free PMC article. Preprint.
Structural models of SARS-CoV-2 Omicron variant in complex with ACE2 receptor or antibodies suggest altered binding interfaces.
Lubin JH, Markosian C, Balamurugan D, Pasqualini R, Arap W, Burley SK, Khare SD. Lubin JH, et al. Among authors: khare sd. bioRxiv [Preprint]. 2021 Dec 13:2021.12.12.472313. doi: 10.1101/2021.12.12.472313. bioRxiv. 2021. Update in: JCI Insight. 2023 Jul 10;8(13):e168296. doi: 10.1172/jci.insight.168296. PMID: 34931193 Free PMC article. Updated. Preprint.
Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells.
Rajasekaran N, Wang X, Ravindranathan S, Chin DJ, Tseng SY, Klakamp SL, Widmann K, Kapoor VN, Vexler V, Keegan P, Yao S, LaVallee T, Khare SD. Rajasekaran N, et al. Among authors: khare sd. Cancer Immunol Immunother. 2024 Feb 24;73(3):60. doi: 10.1007/s00262-024-03635-3. Cancer Immunol Immunother. 2024. PMID: 38400933 Free PMC article.
Corrigendum to "Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus" [Heliyon 9(4) (April 2023) e15032].
Hernandez NE, Jankowski W, Frick R, Kelow SP, Lubin JH, Simhadri V, Adolf-Bryfogle J, Khare SD, Dunbrack RL Jr, Gray JJ, Sauna ZE. Hernandez NE, et al. Among authors: khare sd. Heliyon. 2023 Jul 6;9(8):e17901. doi: 10.1016/j.heliyon.2023.e17901. eCollection 2023 Aug. Heliyon. 2023. PMID: 37701412 Free PMC article.
109 results